BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200:375-382. [PMID: 12845634 DOI: 10.1002/path.1356] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-masson A. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-87. [DOI: 10.1038/sj.onc.1208214] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
2 Park MH, Lee YY, Cho KH, La S, Lee HJ, Yim DS, Ban S, Park MY, Kim YC, Kim YG, Shin YG. Validation of a liquid chromatography-triple quadrupole mass spectrometric method for the determination of 5-nitro-5'-hydroxy-indirubin-3'-oxime (AGM-130) in human plasma and its application to microdose clinical trial. Biomed Chromatogr 2016;30:323-9. [PMID: 26139072 DOI: 10.1002/bmc.3551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Pattison JM, Posternak V, Cole MD. Transcription Factor KLF5 Binds a Cyclin E1 Polymorphic Intronic Enhancer to Confer Increased Bladder Cancer Risk. Mol Cancer Res 2016;14:1078-86. [PMID: 27514407 DOI: 10.1158/1541-7786.MCR-16-0123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007;18:1293-306. [PMID: 17317675 DOI: 10.1093/annonc/mdm013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
5 Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005;18:1305-20. [DOI: 10.1038/modpathol.3800453] [Cited by in Crossref: 108] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
6 Noske A, Henricksen LA, LaFleur B, Zimmermann AK, Tubbs A, Singh S, Storz M, Fink D, Moch H. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. Exp Mol Pathol 2015;98:47-54. [PMID: 25527175 DOI: 10.1016/j.yexmp.2014.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
7 Geng Y, Michowski W, Chick JM, Wang YE, Jecrois ME, Sweeney KE, Liu L, Han RC, Ke N, Zagozdzon A, Sicinska E, Bronson RT, Gygi SP, Sicinski P. Kinase-independent function of E-type cyclins in liver cancer. Proc Natl Acad Sci USA. 2018;115:1015-1020. [PMID: 29339491 DOI: 10.1073/pnas.1711477115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
8 Kok YP, Guerrero Llobet S, Schoonen PM, Everts M, Bhattacharya A, Fehrmann RSN, van den Tempel N, van Vugt MATM. Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis 2020;9:88. [PMID: 33028815 DOI: 10.1038/s41389-020-00270-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
9 Pickett CA, Agoff SN, Widman TJ, Bronner MP. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid 2005;15:461-73. [PMID: 15929668 DOI: 10.1089/thy.2005.15.461] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lambert L, Keyomarsi K. Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel? In: Yu D, Hung M, editors. Breast Cancer Chemosensitivity. New York: Springer; 2007. pp. 52-69. [DOI: 10.1007/978-0-387-74039-3_4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 2018;78:5481-91. [PMID: 30194068 DOI: 10.1158/0008-5472.CAN-18-1235] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
12 Freier K, Knoepfle K, Flechtenmacher C, Pungs S, Devens F, Toedt G, Hofele C, Joos S, Lichter P, Radlwimmer B. Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma. Genes Chromosomes Cancer 2010;49:9-16. [PMID: 19787784 DOI: 10.1002/gcc.20714] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
13 Pahl PMB, Horwitz LD. Cell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents. Cancer Investigation 2009;23:683-91. [DOI: 10.1080/07357900500359976] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
14 White J, Dalton S. Cell cycle control of embryonic stem cells. Stem Cell Rev 2005;1:131-8. [PMID: 17142847 DOI: 10.1385/SCR:1:2:131] [Cited by in Crossref: 223] [Cited by in F6Publishing: 150] [Article Influence: 15.9] [Reference Citation Analysis]
15 Tonks ID, Mould AW, Schroder WA, Cotterill A, Hayward NK, Walker GJ, Kay GF. Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia 2010;12:235-43. [PMID: 20234817 DOI: 10.1593/neo.91646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Yang G, Xiong G, Cao Z, Zheng S, You L, Zhang T, Zhao Y. miR-497 expression, function and clinical application in cancer. Oncotarget. 2016;7:55900-55911. [PMID: 27344185 DOI: 10.18632/oncotarget.10152] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
17 Callagy G, Pharoah P, Chin SF, Sangan T, Daigo Y, Jackson L, Caldas C. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205:388-96. [PMID: 15682439 DOI: 10.1002/path.1694] [Cited by in Crossref: 107] [Cited by in F6Publishing: 84] [Article Influence: 6.7] [Reference Citation Analysis]
18 Zschemisch N, Liedtke C, Dierssen U, Nevzorova YA, Wüstefeld T, Borlak J, Manns MP, Trautwein C. Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytesin vivo. Hepatology 2006;44:164-73. [DOI: 10.1002/hep.21224] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
19 Drenckhan A, Freytag M, Supuran CT, Sauter G, Izbicki JR, Gros SJ. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. J Enzyme Inhib Med Chem 2018;33:1024-33. [PMID: 29865880 DOI: 10.1080/14756366.2018.1475369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
20 Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007;25:468-75. [PMID: 18047954 DOI: 10.1016/j.urolonc.2006.09.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
21 Lee MC, Hsieh CH, Wei SC, Shen SC, Chen CN, Wu VC, Chuang LY, Hsieh FJ, Wu CH, Tsai-Wu JJ. Ectopic EBP2 expression enhances cyclin E1 expression and induces chromosome instability in HEK293 stable clones. BMB Rep 2008;41:716-21. [PMID: 18959818 DOI: 10.5483/bmbrep.2008.41.10.716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, Han SY, Kim JI, Kim YC. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 2010;53:3696-706. [PMID: 20361800 DOI: 10.1021/jm100080z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
23 Weroha SJ, Lingle WL, Hong Y, Li SA, Li JJ. Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen. HORM CANC 2010;1:34-43. [DOI: 10.1007/s12672-009-0004-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
24 Bonelli P, Tuccillo FM, Borrelli A, Schiattarella A, Buonaguro FM. CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity. Biomed Res Int 2014;2014:361020. [PMID: 24605326 DOI: 10.1155/2014/361020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
25 Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E Amplification and Overexpression in Clear Cell Adenocarcinoma of the Ovary. Oncology 2004;67:291-9. [DOI: 10.1159/000081330] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
26 Theurillat JP, Metzler SC, Henzi N, Djouder N, Helbling M, Zimmermann AK, Jacob F, Soltermann A, Caduff R, Heinzelmann-Schwarz V. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell. 2011;19:317-332. [PMID: 21397856 DOI: 10.1016/j.ccr.2011.01.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
27 Søiland H, Skaland I, van Diermen B, Janssen EA, Körner H, Varhaug JE, Søreide JA, Baak JP. Androgen Receptor Determination in Breast Cancer: A Comparison of the Dextran-coated Charcoal Method and Quantitative Immunohistochemical Analysis. Applied Immunohistochemistry & Molecular Morphology 2008;16:362-70. [DOI: 10.1097/pai.0b013e31815b9c92] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Bisteau X, Caldez MJ, Kaldis P. The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) 2014;6:79-111. [PMID: 24419005 DOI: 10.3390/cancers6010079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
29 Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, Coukos G, Damle N, Godfrey TE, Howell WM, Panelli MC, Perricone MA, Petricoin EF, Sauter G, Scheibenbogen C, Shivers SC, Taylor DL, Weinstein JN, Whiteside TL. Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients: A Meeting Held at the Masur Auditorium, National Institutes of Health. Journal of Immunotherapy 2005;28:79-119. [DOI: 10.1097/01.cji.0000154251.20125.2e] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
30 Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, Sauter G, Steurer S, Clauditz TS, Wilczak W. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep 2018;39:3-12. [PMID: 29115542 DOI: 10.3892/or.2017.6072] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
31 Madka V, Mohammed A, Li Q, Zhang Y, Patlolla JM, Biddick L, Lightfoot S, Wu XR, Steele V, Kopelovich L, Rao CV. Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice. Cancer Prev Res (Phila) 2014;7:708-16. [PMID: 24795386 DOI: 10.1158/1940-6207.CAPR-14-0087] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
32 Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IeM, Wang TL. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-7. [PMID: 17351921 DOI: 10.1002/ijc.22609] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 6.6] [Reference Citation Analysis]
33 Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005;90:5-14. [PMID: 15770521 DOI: 10.1007/s10549-004-1536-0] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 7.3] [Reference Citation Analysis]
34 Conradie R, Bruggeman FJ, Ciliberto A, Csikász-nagy A, Novák B, Westerhoff HV, Snoep JL. Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex: Restriction point control of the mammalian cell cycle. FEBS Journal 2010;277:357-67. [DOI: 10.1111/j.1742-4658.2009.07473.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
35 Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol. 2012;6:335-341. [PMID: 22646255 DOI: 10.1586/egh.12.7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
36 Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005;24:2776-2786. [PMID: 15838514 DOI: 10.1038/sj.onc.1208613] [Cited by in Crossref: 292] [Cited by in F6Publishing: 292] [Article Influence: 18.3] [Reference Citation Analysis]
37 Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Human Pathology 2006;37:1568-76. [DOI: 10.1016/j.humpath.2006.05.017] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
38 Shergill IS, Rao AR, Anjum FH, Arya M, Patel HR, Mundy AR. Tissue microarrays and their relevance to the urologist. J Urol. 2006;175:19-26. [PMID: 16406863 DOI: 10.1016/s0022-5347(05)00019-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, Clarke PA, Workman P, Blake D, Zheleva D. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One 2020;15:e0234103. [PMID: 32645016 DOI: 10.1371/journal.pone.0234103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
40 He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9. [PMID: 28446688 DOI: 10.1126/scitranslmed.aal3986] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 20.0] [Reference Citation Analysis]
41 Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, Chiba T. Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers. Int J Cancer. 2009;125:2029-2035. [PMID: 19585504 DOI: 10.1002/ijc.24565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
42 Xia J, Mei Q, Rosenberg SM. Tools To Live By: Bacterial DNA Structures Illuminate Cancer. Trends Genet 2019;35:383-95. [PMID: 30962000 DOI: 10.1016/j.tig.2019.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
43 Liu S, Tang H, Zhu J, Ding H, Zeng Y, Du W, Ding Z, Song P, Zhang Y, Liu Z, Huang JA. High expression of Copine 1 promotes cell growth and metastasis in human lung adenocarcinoma. Int J Oncol 2018;53:2369-78. [PMID: 30221693 DOI: 10.3892/ijo.2018.4558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
44 Palmer N, Kaldis P. Less-well known functions of cyclin/CDK complexes. Semin Cell Dev Biol 2020;107:54-62. [PMID: 32386818 DOI: 10.1016/j.semcdb.2020.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Honrado E, Benítez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol 2006;59:27-39. [PMID: 16530420 DOI: 10.1016/j.critrevonc.2006.01.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
46 Obermann EC, Went P, Zimpfer A, Tzankov A, Wild PJ, Stoehr R, Pileri SA, Dirnhofer S. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer 2005;5:162. [PMID: 16368013 DOI: 10.1186/1471-2407-5-162] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
47 Simon R. Applications of tissue microarray technology. Methods Mol Biol 2010;664:1-16. [PMID: 20690047 DOI: 10.1007/978-1-60761-806-5_1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Bie LY, Li D, Mu Y, Wang S, Chen BB, Lyu HF, Han LL, Nie CY, Yang CC, Wang L, Ren CC, Zhang WJ, Guo P, Shi F, Fan QX, Wang LX, Chen XB, Luo SX. Analysis of cyclin E co-expression genes reveals nuclear transcription factor Y subunit alpha is an oncogene in gastric cancer. Chronic Dis Transl Med 2019;5:44-52. [PMID: 30993263 DOI: 10.1016/j.cdtm.2018.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gu J, Wu X. Genetic susceptibility to bladder cancer risk and outcome. Per Med 2011;8:365-74. [PMID: 21927616 DOI: 10.2217/pme.11.15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
50 Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG. Cyclins and cell cycle control in cancer and disease. Genes Cancer 2012;3:649-57. [PMID: 23634253 DOI: 10.1177/1947601913479022] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 16.4] [Reference Citation Analysis]
51 Choi RS, Lai WYX, Lee LTC, Wong WLC, Pei XM, Tsang HF, Leung JJ, Cho WCS, Chu MKM, Wong EYL, Wong SCC. Current and future molecular diagnostics of gastric cancer. Expert Rev Mol Diagn 2019;19:863-74. [PMID: 31448971 DOI: 10.1080/14737159.2019.1660645] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
52 Ahlin C, Gruhne B, Holmqvist M, Zetterberg A, Fjällskog M. Aberrant expression of cyclin E in low-risk node negative breast cancer. Acta Oncologica 2009;47:1539-45. [DOI: 10.1080/02841860701856581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Ma D, Zhou Z, Yang B, He Q, Zhang Q, Zhang XH. Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining. Oncol Lett 2015;10:2185-91. [PMID: 26622816 DOI: 10.3892/ol.2015.3556] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wirries A, Breyer S, Quint K, Schobert R, Ocker M. Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells. Exp Ther Med 2010;1:369-75. [PMID: 22993551 DOI: 10.3892/etm_00000058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
55 Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 2012;11:1468-76. [PMID: 22441703 DOI: 10.4161/cc.19882] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
56 Zhou Y, Geng Y, Zhang Y, Zhou Y, Chu C, Sharma S, Fassl A, Butter D, Sicinski P. The requirement for cyclin E in c-Myc overexpressing breast cancers. Cell Cycle 2020;19:2589-99. [PMID: 32975478 DOI: 10.1080/15384101.2020.1804720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res 2004;6:188-91. [PMID: 15318923 DOI: 10.1186/bcr905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
58 Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol 2012; 18(11): 1249-1256 [PMID: 22468089 DOI: 10.3748/wjg.v18.i11.1249] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
59 Wiedemeyer WR. Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors. In: Yarden Y, Elkabets M, editors. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Cham: Springer International Publishing; 2018. pp. 181-210. [DOI: 10.1007/978-3-319-67932-7_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
60 Rathje LS, Nordgren N, Pettersson T, Rönnlund D, Widengren J, Aspenström P, Gad AK. Oncogenes induce a vimentin filament collapse mediated by HDAC6 that is linked to cell stiffness. Proc Natl Acad Sci U S A 2014;111:1515-20. [PMID: 24474778 DOI: 10.1073/pnas.1300238111] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
61 van Drogen F, Sangfelt O, Malyukova A, Matskova L, Yeh E, Means AR, Reed SI. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell 2006;23:37-48. [PMID: 16818231 DOI: 10.1016/j.molcel.2006.05.020] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 5.3] [Reference Citation Analysis]
62 Orlando L, Renne G, Rocca A, Curigliano G, Colleoni M, Severi G, Peruzzotti G, Viale G, Sanna G, Goldhirsch A, Cinieri S. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Annals of Oncology 2005;16:1094-9. [DOI: 10.1093/annonc/mdi213] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
63 Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol 2016;186:1900-12. [PMID: 27182644 DOI: 10.1016/j.ajpath.2016.02.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
64 Teixeira LK, Reed SI. Cyclin E Deregulation and Genomic Instability. Adv Exp Med Biol 2017;1042:527-47. [PMID: 29357072 DOI: 10.1007/978-981-10-6955-0_22] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
65 Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang Y, Yang C, Jiang Y. miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget 2015;6:13149-63. [PMID: 25909221 DOI: 10.18632/oncotarget.3693] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
66 Leung SY, Ho C, Tu IP, Li R, So S, Chu KM, Yuen ST, Chen X. Comprehensive analysis of 19q12 amplicon in human gastric cancers. Mod Pathol. 2006;19:854-863. [PMID: 16575401 DOI: 10.1038/modpathol.3800593] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
67 Ye L, Guo L, He Z, Wang X, Lin C, Zhang X, Wu S, Bao Y, Yang Q, Song L, Lin H. Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. Oncotarget 2016;7:23757-71. [PMID: 26992224 DOI: 10.18632/oncotarget.8121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
68 Kramer MW, Merseburger AS, Hennenlotter J, Kuczyk M. Tissue microarrays in clinical urology--technical considerations. Scand J Urol Nephrol 2007;41:478-84. [PMID: 17907050 DOI: 10.1080/00365590701430737] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
69 Bélanger H, Beaulieu P, Moreau C, Labuda D, Hudson TJ, Sinnett D. Functional promoter SNPs in cell cycle checkpoint genes. Hum Mol Genet 2005;14:2641-8. [PMID: 16081466 DOI: 10.1093/hmg/ddi298] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
70 Dong L, Yu L, Bai C, Liu L, Long H, Shi L, Lin Z. USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis. Oncogene 2018;37:2702-13. [PMID: 29497124 DOI: 10.1038/s41388-018-0137-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
71 Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011;108:3761-6. [PMID: 21321214 DOI: 10.1073/pnas.1014835108] [Cited by in Crossref: 195] [Cited by in F6Publishing: 186] [Article Influence: 19.5] [Reference Citation Analysis]
72 Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM. Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Ther Med. 2010;1:789-797. [PMID: 22993603 DOI: 10.3892/etm.2010.116] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
73 Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010. [DOI: 10.1002/cncr.24987] [Cited by in Crossref: 18] [Cited by in F6Publishing: 80] [Article Influence: 1.6] [Reference Citation Analysis]
74 Kanska J, Zakhour M, Taylor-harding B, Karlan B, Wiedemeyer W. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. Gynecologic Oncology 2016;143:152-8. [DOI: 10.1016/j.ygyno.2016.07.111] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
75 Tessema M, Lehmann U, Kreipe H. Cell cycle and no end. Virchows Arch 2004;444:313-23. [PMID: 14968363 DOI: 10.1007/s00428-003-0971-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
76 Keenan SM, Lents NH, Baldassare JJ. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor supresssor protein, activation of E2F, and G1-S phase prgression. J Biol Chem. 2004;279:5387-5396. [PMID: 14645251 DOI: 10.1074/jbc.M310383200] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
77 Shih I, Kurman RJ. Pathogenesis of Gestational Trophoblastic Lesions. In: Giordano A, Bovicelli A, Kurman RJ, editors. Molecular Pathology of Gynecologic Cancer. Totowa: Humana Press; 2007. pp. 157-66. [DOI: 10.1007/978-1-59745-346-2_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
78 Machida YJ, Teer JK, Dutta A. Acute Reduction of an Origin Recognition Complex (ORC) Subunit in Human Cells Reveals a Requirement of ORC for Cdk2 Activation. Journal of Biological Chemistry 2005;280:27624-30. [DOI: 10.1074/jbc.m502615200] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
79 Rodríguez-pinilla SM, Rodríguez-gil Y, Moreno-bueno G, Sarrió D, Martín-guijarro MDC, Hernandez L, Palacios J. Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype: An Immunohistochemical and Gene Amplification Study. American Journal of Surgical Pathology 2007;31:501-8. [DOI: 10.1097/01.pas.0000213427.84245.92] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
80 Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004;22:4514-4522. [PMID: 15542802 DOI: 10.1200/jco.2004.10.125] [Cited by in Crossref: 157] [Cited by in F6Publishing: 56] [Article Influence: 9.2] [Reference Citation Analysis]
81 Myllykangas S, Böhling T, Knuutila S. Specificity, selection and significance of gene amplifications in cancer. Semin Cancer Biol 2007;17:42-55. [PMID: 17161620 DOI: 10.1016/j.semcancer.2006.10.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
82 Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007;8:258. [PMID: 17663798 DOI: 10.1186/1471-2164-8-258] [Cited by in Crossref: 198] [Cited by in F6Publishing: 184] [Article Influence: 14.1] [Reference Citation Analysis]
83 Obermann EC, Went P, Tzankov A, Pileri SA, Hofstaedter F, Marienhagen J, Stoehr R, Dirnhofer S. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol 2007;60:794-7. [PMID: 16950856 DOI: 10.1136/jcp.2006.040956] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
84 Aaltonen K, Ahlin C, Amini RM, Salonen L, Fjällskog ML, Heikkilä P, Nevanlinna H, Blomqvist C. Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 2006;94:1697-702. [PMID: 16670718 DOI: 10.1038/sj.bjc.6603147] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
85 Mao T, Seidman JD, Kurman RJ, Shih I. Cyclin E and p16 Immunoreactivity in Epithelioid Trophoblastic Tumor???An Aid in Differential Diagnosis: . The American Journal of Surgical Pathology. [DOI: 10.1097/01.pas.0000209854.28282.87] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
86 Nagel I, Akasaka T, Klapper W, Gesk S, Böttcher S, Ritgen M, Harder L, Kneba M, Dyer MJ, Siebert R. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica 2009;94:1020-3. [PMID: 19454496 DOI: 10.3324/haematol.2008.000968] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
87 Lents NH, Baldassare JJ. CDK2 and cyclin E knockout mice: lessons from breast cancer. Trends in Endocrinology & Metabolism 2004;15:1-3. [DOI: 10.1016/j.tem.2003.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
88 Song BN, Kim SK, Chu IS. Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer. Exp Mol Med 2017;49:e282. [PMID: 28082741 DOI: 10.1038/emm.2016.120] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
89 Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ, Reed MW. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 2007;121:1009-16. [PMID: 17471570 DOI: 10.1002/ijc.22772] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
90 Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol. 2004;165:789-800. [PMID: 15197178 DOI: 10.1083/jcb.200404092] [Cited by in Crossref: 203] [Cited by in F6Publishing: 197] [Article Influence: 11.9] [Reference Citation Analysis]
91 Kumari S, Puneet, Prasad SB, Yadav SS, Kumar M, Khanna A, Dixit VK, Nath G, Singh S, Narayan G. Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer. Med Oncol 2016;33. [DOI: 10.1007/s12032-016-0754-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
92 Gorges LL, Lents NH, Baldassare JJ. The extreme COOH terminus of the retinoblastoma tumor suppressor protein pRb is required for phosphorylation on Thr-373 and activation of E2F. Am J Physiol Cell Physiol 2008;295:C1151-60. [PMID: 18768921 DOI: 10.1152/ajpcell.00300.2008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
93 Inoue K, Fry EA. Novel Molecular Markers for Breast Cancer. Biomark Cancer 2016;8:25-42. [PMID: 26997872 DOI: 10.4137/BIC.S38394] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
94 Montazeri H, Bouzari S, Azadmanesh K, Ostad SN, Ghahremani MH. Divergent behavior of cyclin E and its low molecular weight isoforms to progesterone-induced growth inhibition in MCF-7 cells. Adv Biomed Res 2015;4:16. [PMID: 25625122 DOI: 10.4103/2277-9175.148299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]